Cargando…

QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL

OBJECTIVES: Reduced neuropsychological outcomes are a major concern in pediatric patients with malignant brain tumors. We aimed to estimate decline in cognitive function according to treatment regimens. METHODS: Cross-sectional analysis of cognitive functions tested with the Neuropsychological Basic...

Descripción completa

Detalles Bibliográficos
Autores principales: Mynarek, Martin, Neumann-Holbeck, Anne, Resch, Anika, Ottensmeier, Holger, von Hoff, Katja, Traunwieser, Thomas, Kortmann, Rolf-Dieter, Obrecht, Denise, Warmuth-Metz, Monika, Bison, Brigitte, Pietsch, Torsten, Pfister, Stefan M, Sill, Martin, Kool, Marcel, Sturm, Dominik, Jones, David, von Deimling, Andreas, Sahm, Felix, Tischler, Tanja, Rutkowski, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715612/
http://dx.doi.org/10.1093/neuonc/noaa222.676
_version_ 1783618996374863872
author Mynarek, Martin
Neumann-Holbeck, Anne
Resch, Anika
Ottensmeier, Holger
von Hoff, Katja
Traunwieser, Thomas
Kortmann, Rolf-Dieter
Obrecht, Denise
Warmuth-Metz, Monika
Bison, Brigitte
Pietsch, Torsten
Pfister, Stefan M
Sill, Martin
Kool, Marcel
Sturm, Dominik
Jones, David
von Deimling, Andreas
Sahm, Felix
Tischler, Tanja
Rutkowski, Stefan
author_facet Mynarek, Martin
Neumann-Holbeck, Anne
Resch, Anika
Ottensmeier, Holger
von Hoff, Katja
Traunwieser, Thomas
Kortmann, Rolf-Dieter
Obrecht, Denise
Warmuth-Metz, Monika
Bison, Brigitte
Pietsch, Torsten
Pfister, Stefan M
Sill, Martin
Kool, Marcel
Sturm, Dominik
Jones, David
von Deimling, Andreas
Sahm, Felix
Tischler, Tanja
Rutkowski, Stefan
author_sort Mynarek, Martin
collection PubMed
description OBJECTIVES: Reduced neuropsychological outcomes are a major concern in pediatric patients with malignant brain tumors. We aimed to estimate decline in cognitive function according to treatment regimens. METHODS: Cross-sectional analysis of cognitive functions tested with the Neuropsychological Basic Diagnostic tool (NBD) in 279 patients >4 years at diagnosis (median: 8.66; range: 4.01–18.98) with medulloblastoma (n=110, 23.7–25.0Gy CSI; n=131, >30Gy CSI) or posterior fossa ependymoma (n=38 local radiotherapy) who participated in the HIT-2000 trial. Multivariable regression analysis was conducted to adjust for postoperative cerebellar mutism syndrome, preoperative hydrocephalus, postoperative shunt placement, the interval between diagnosis and assessment, sex and age. RESULTS: Mean time from diagnosis to assessment was 5.1 years. Increasing CSI-dose was significantly associated with a deterioration in performance of most subtests, particularly in areas of fluid intelligence (mean z-values per test for no CSI/23.4Gy/>30Gy respectively: matrix reasoning:-0.40/-0.52/-0.98, p<.001), short-term memory (number recall: -0.07/-0.58/-0.64, p=.002), visuo-spatial skills (visual-motor integration:-0.49/-0.68/-1.12, p<.001) and fine motor skills (dominant-hand:-1.09/-1.80/-2.12, p=.008; non-dominant-hand:-1.47/-2.59/-2.82, p=.003; bimanual coordination:-1.33/-2.68/-2.76, p=.001). These differences were retained after adjustment for confounding variables. Within medulloblastoma patients treated with >30Gy CSI, selective attention, but no other function was reduced in patients treated with pre-radiotherapy chemotherapy including intraventricular MTX (selective attention (with chemotherapy/without chemotherapy mean z-values: -0.66/0.00, p=.006)). Patients with SHH-activated medulloblastoma did significantly better than WNT or Group3/Group4 medulloblastoma patients in fluid intelligence and fine motor skills. CONCLUSION: CSI dose among other highly relevant factors had significant effects on neuropsychological outcome. Pre-radiotherapy intraventricular MTX had only minor effects. Patients with SHH-activated medulloblastomas showed a more favorable outcome when compared to patients in the other subgroups.
format Online
Article
Text
id pubmed-7715612
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77156122020-12-09 QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL Mynarek, Martin Neumann-Holbeck, Anne Resch, Anika Ottensmeier, Holger von Hoff, Katja Traunwieser, Thomas Kortmann, Rolf-Dieter Obrecht, Denise Warmuth-Metz, Monika Bison, Brigitte Pietsch, Torsten Pfister, Stefan M Sill, Martin Kool, Marcel Sturm, Dominik Jones, David von Deimling, Andreas Sahm, Felix Tischler, Tanja Rutkowski, Stefan Neuro Oncol Neuropsychology/Quality of Life OBJECTIVES: Reduced neuropsychological outcomes are a major concern in pediatric patients with malignant brain tumors. We aimed to estimate decline in cognitive function according to treatment regimens. METHODS: Cross-sectional analysis of cognitive functions tested with the Neuropsychological Basic Diagnostic tool (NBD) in 279 patients >4 years at diagnosis (median: 8.66; range: 4.01–18.98) with medulloblastoma (n=110, 23.7–25.0Gy CSI; n=131, >30Gy CSI) or posterior fossa ependymoma (n=38 local radiotherapy) who participated in the HIT-2000 trial. Multivariable regression analysis was conducted to adjust for postoperative cerebellar mutism syndrome, preoperative hydrocephalus, postoperative shunt placement, the interval between diagnosis and assessment, sex and age. RESULTS: Mean time from diagnosis to assessment was 5.1 years. Increasing CSI-dose was significantly associated with a deterioration in performance of most subtests, particularly in areas of fluid intelligence (mean z-values per test for no CSI/23.4Gy/>30Gy respectively: matrix reasoning:-0.40/-0.52/-0.98, p<.001), short-term memory (number recall: -0.07/-0.58/-0.64, p=.002), visuo-spatial skills (visual-motor integration:-0.49/-0.68/-1.12, p<.001) and fine motor skills (dominant-hand:-1.09/-1.80/-2.12, p=.008; non-dominant-hand:-1.47/-2.59/-2.82, p=.003; bimanual coordination:-1.33/-2.68/-2.76, p=.001). These differences were retained after adjustment for confounding variables. Within medulloblastoma patients treated with >30Gy CSI, selective attention, but no other function was reduced in patients treated with pre-radiotherapy chemotherapy including intraventricular MTX (selective attention (with chemotherapy/without chemotherapy mean z-values: -0.66/0.00, p=.006)). Patients with SHH-activated medulloblastoma did significantly better than WNT or Group3/Group4 medulloblastoma patients in fluid intelligence and fine motor skills. CONCLUSION: CSI dose among other highly relevant factors had significant effects on neuropsychological outcome. Pre-radiotherapy intraventricular MTX had only minor effects. Patients with SHH-activated medulloblastomas showed a more favorable outcome when compared to patients in the other subgroups. Oxford University Press 2020-12-04 /pmc/articles/PMC7715612/ http://dx.doi.org/10.1093/neuonc/noaa222.676 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Neuropsychology/Quality of Life
Mynarek, Martin
Neumann-Holbeck, Anne
Resch, Anika
Ottensmeier, Holger
von Hoff, Katja
Traunwieser, Thomas
Kortmann, Rolf-Dieter
Obrecht, Denise
Warmuth-Metz, Monika
Bison, Brigitte
Pietsch, Torsten
Pfister, Stefan M
Sill, Martin
Kool, Marcel
Sturm, Dominik
Jones, David
von Deimling, Andreas
Sahm, Felix
Tischler, Tanja
Rutkowski, Stefan
QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL
title QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL
title_full QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL
title_fullStr QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL
title_full_unstemmed QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL
title_short QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL
title_sort qol-13. neurocognitive outcomes according to risk-adapted treatment regimens for children older than 4 with medulloblastoma and posterior fossa ependymoma – results of the hit2000 trial
topic Neuropsychology/Quality of Life
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715612/
http://dx.doi.org/10.1093/neuonc/noaa222.676
work_keys_str_mv AT mynarekmartin qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT neumannholbeckanne qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT reschanika qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT ottensmeierholger qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT vonhoffkatja qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT traunwieserthomas qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT kortmannrolfdieter qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT obrechtdenise qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT warmuthmetzmonika qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT bisonbrigitte qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT pietschtorsten qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT pfisterstefanm qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT sillmartin qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT koolmarcel qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT sturmdominik qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT jonesdavid qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT vondeimlingandreas qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT sahmfelix qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT tischlertanja qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial
AT rutkowskistefan qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial